Skip to content
OpenCapital
Get started

Protalix BioTherapeutics, Inc. PLX Q4 2025 Annual earnings

Reported March 18, 2026 · Before market open

Revenue$9.1MMiss by $9.2MDiluted EPS-$0.07Miss by $0.08
Revenue estimate$18.3M
EPS estimate$0.01

Next report

Aug 13, 2026 (in a month)
Revenue estimate$13.0M
EPS estimate-$0.01

Versus estimates

Revenue

Q1 2026$33.8MBeat by $22.3M
Q4 2025$9.1MMiss by $9.2M
Q3 2025$17.9MBeat by $3.6MQ2 2025$15.7MBeat by $2.2MQ1 2025$10.1MMiss by $13.0MQ4 2024$18.2MMiss by $3.4M

Diluted EPS

Q1 2026$0.22Beat by $0.23
Q4 2025-$0.07Miss by $0.08
Q3 2025$0.03Miss by $0.03Q2 2025$0.00Miss by $0.03Q1 2025-$0.05Miss by $0.13Q4 2024$0.09Beat by $0.02

Ask the moment Protalix BioTherapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Protalix BioTherapeutics, Inc. report Q4 2025 earnings?
Protalix BioTherapeutics, Inc. (PLX) reported Q4 2025 earnings on March 18, 2026 before market open.
What were Protalix BioTherapeutics, Inc.'s Q4 2025 revenue and EPS?
Protalix BioTherapeutics, Inc. reported revenue of $9.1M and diluted EPS of $-0.07 for Q4 2025.
Did Protalix BioTherapeutics, Inc. beat estimates in Q4 2025?
Revenue missed the consensus estimate of $18.3M by $9.2M. EPS missed the consensus estimate of $0.01 by $0.08.
How did Protalix BioTherapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 49.9% from $18.2M a year earlier.
Where can I find Protalix BioTherapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001104659-26-029846) and the 10-K periodic report (0001104659-26-029858) directly on SEC EDGAR. The filing index links above go to sec.gov.